论文部分内容阅读
目的 :比较国产头孢地嗪和莫敌 (进口头孢地嗪 )治疗泌尿系统感染的临床疗效和安全性。方法 :采用多中心随机双盲对照方法 ,每组 30例 ,两药剂量均为 2 g/次 ,q12h ,静滴 ,疗程 7～ 14d。 结果 :头孢地嗪组和莫敌组的临床痊愈率分别为 86 .7%和 76 .7% ;有效率分别为 96 .7%和 90 .0 % ;细菌清除率均为 10 0 % ;不良反应发生率分别为 3.3%及 6 .6 %。经统计学处理 ,无显著性差异 (P >0 .0 5 )。结论 :国产头孢地嗪治疗泌尿系统感染性疾病安全、有效 ,与莫敌生物等效。
Objective: To compare the clinical efficacy and safety of domestic cefodizime and prophylaxis (imported cefodizime) in the treatment of urinary tract infections. Methods: A multicenter, randomized, double-blind, controlled trial was conducted in 30 patients in each group. The doses of the two drugs were 2 g / dose q12h for 7-14 days. Results: The clinical cure rates were 86.7% and 76.7% in cefodizime group and Mo enemy group respectively; the effective rates were 96.7% and 90.0% respectively; the bacterial clearance rate was 100% Response rates were 3.3% and 6.6% respectively. Statistically, no significant difference (P> 0.05). CONCLUSION: Domestic cefodizime is safe and effective in the treatment of urinary tract infectious diseases and is bioequivalent to those of the enemy.